| Literature DB >> 27704215 |
Caroline Furtado Noble1,2, Fernanda Malta3,4, Gaspar Lisboa-Neto5, Michele Soares Gomes-Gouvêa1,2, Andrea Gurgel Batista Leite6, Vanessa Fusco Duarte de Castro7, Rubia Anita Ferraz Santana7, Flair José Carrilho2, Maria Cássia Mendes-Correa5,8, João Renato Rebello Pinho1,2,7.
Abstract
Resistance-associated variants (RAVs) represent a challenge to the success of new HCV therapies. The aim of this study was to describe the prevalence of naturally occurring NS5B RAVs in Brazilian direct acting antivirals (DAA)-naïve patients infected with HCV genotype 1, or co-infected with HIV. Patient enrollment and sample collection were performed between 2011 and 2013. Using Sanger-based sequencing, 244 sequences were obtained. RAVs detected in HCV-1a sequences were V321A (1.6 %), M414V (1.3 %), A421V (21.4-23.7 %), A421G (1.3 %) and Y448H (1.3 %); and in HCV-1b sequences were L159F (16.1 %), C316N (7.1-16.3 %) and A421V (3.2-6.3 %). Understanding the real RAVs scenario in patients is fundamental to establishing the most effective therapeutic strategy and in minimizing the risks for their selection.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27704215 DOI： 10.1007/s00705-016-3094-2
Source DB: PubMed Journal: Arch Virol ISSN： 0304-8608 Impact factor: 2.574